- Home
- CMMB vs LSTA Comparison
CMMB vs LSTA Comparison
Compare CMMB & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMMB
- LSTA
- Stock Information
- Founded
- CMMB 2004
- LSTA 1980
- Country
- CMMB Israel
- LSTA United States
- Employees
- CMMB N/A
- LSTA N/A
- Industry
- CMMB Biotechnology: Pharmaceutical Preparations
- LSTA Misc Health and Biotechnology Services
- Sector
- CMMB Health Care
- LSTA Health Care
- Exchange
- CMMB Nasdaq
- LSTA Nasdaq
- Market Cap
- CMMB 23.6M
- LSTA 20.0M
- IPO Year
- CMMB N/A
- LSTA N/A
- Fundamental
- Price
- CMMB $1.20
- LSTA $2.39
- Analyst Decision
- CMMB Strong Buy
- LSTA Strong Buy
- Analyst Count
- CMMB 2
- LSTA 1
- Target Price
- CMMB $9.00
- LSTA $15.00
- AVG Volume (30 Days)
- CMMB 167.2K
- LSTA 13.3K
- Earning Date
- CMMB 05-08-2025
- LSTA 05-08-2025
- Dividend Yield
- CMMB N/A
- LSTA N/A
- EPS Growth
- CMMB N/A
- LSTA N/A
- EPS
- CMMB N/A
- LSTA N/A
- Revenue
- CMMB N/A
- LSTA $1,000,000.00
- Revenue This Year
- CMMB N/A
- LSTA N/A
- Revenue Next Year
- CMMB N/A
- LSTA N/A
- P/E Ratio
- CMMB N/A
- LSTA N/A
- Revenue Growth
- CMMB N/A
- LSTA N/A
- 52 Week Low
- CMMB $0.58
- LSTA $1.87
- 52 Week High
- CMMB $2.55
- LSTA $4.20
- Technical
- Relative Strength Index (RSI)
- CMMB 50.27
- LSTA 60.67
- Support Level
- CMMB $1.08
- LSTA $1.91
- Resistance Level
- CMMB $1.25
- LSTA $2.09
- Average True Range (ATR)
- CMMB 0.11
- LSTA 0.18
- MACD
- CMMB 0.04
- LSTA 0.06
- Stochastic Oscillator
- CMMB 83.65
- LSTA 100.00
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.
About LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Its product candidate, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively.